First author (year) Regions Study design Number of total Pts Age (year) Male (%) Etiology of cirrhosis HCC (%) Child-Pugh class (%) Location of varices Prevalence of varices (%) Prevalence of high-risk/large varices (%) Cut-off of varices Karatzas (2016) Greece Prospective 38 63 78.9% Alcohol 47.4% NA A, 55.3% EV + GV 63.2% 10.5% 1310.597 (optimal) Viral hepatitis 34.2% B, 28.9% Others 18.4% C, 15.8% 909 Kim (2016) South Korea Retrospective 103 53.5 ± 11.8 65.0% Alcohol 28.2% NA NA EV 38.8% 12.6% 860 HBV 50.5% HCV 8.7% HBV and alcohol 7.8% Others 4.9% Takuma (2016) Japan Prospective 60 70.8 ± 9.9 56.7% Alcohol 10% NA A, 68.3% EV 40.0% 26.7% 3.36 HBV 13.3% HCV 58.3% Others 18.3% Xu (2016) China Prospective 236 61.4 ± 10.2 43.2% Schistosomiasis 100% NA NA EV 40.3% NA 1004 (optimal) 909 Albreedy (2015) Egypt Prospective 100 44.24 ± 7.05 58.0% NA 0% A, 41% EV 66.0% 47.0% 979.9 B, 33% C, 26% Cho (2015) South Korea Retrospective 219 91.8% Alcohol 100% 0% A, 59.4% EV + GV NA 33.3% NA B, 36.1% C, 4.6% Stefanescu (2015) Romania Cross-sectional 90 56.47 ± 9.38/ 55.6% Alcohol 33.3% 0% A, 62.2% EV 81.1% 52.2% NA HBV 13.3% HCV 33.3% Others 20% Valero (2015) (abstract) Philippines Retrospective 101 64.8/61.6 NA NA 0% NA EV 85.1% NA 1.86 Zhao (2015) China Retrospective 124 51.34 ± 11.089 57.3% HCV 100% NA NA EV 51.6% NA 909 Chiodi (2014) Uruguay Retrospective 125 54 56.8% Alcohol 40% 0% NA EV 63.2% 42.4% 1010% HBV 3.2% HCV 16.8% Autoimmune 12% Others 19.2% Unknown 8.8 González-Ojeda (2014) Mexico Cross-sectional 91 53.75 ± 12 54.9% Alcohol 52.7% 0% A, 18.7% EV 80.2% 57.1% 884 HCV 26.4% Others 11% Unknown 10% Wang (2014) China Retrospective 104 59 56.7% Alcohol 17.3% NA A, 24% EV 99.0% 51.9% NA HBV 66.3% Alcohol and HBV 12.5% Unknown 3.8% Zafar (2014) Pakistan Prospective 215 46.93 ± 13.22 42.3% NA NA NA EV 60.9% NA 909 Calvaruso (2013) Italy Prospective 96 63.2 ± 9.5 69.8% HCV 100% 0% A, 100% EV 56.3% 27.1% 800 Masjedizadeh (2013) Iran Prospective 140 57/53 70.0% Alcohol 3.6% NA A, 43.6% EV 85.0% 33.6% 663 HBV 36.4% HCV 17.1% Autoimmune 8.6% Others 5.7% Unknown 28.6% Rajendran (2013) (abstract) India Cross-sectional 101 NA 93.1% Alcohol 85% NA NA EV 95.0% 65.0% NA HBV 9% HCV 5% Saad (2013) Egypt NA 32 55 ± 6.6/49.5 ± 4.7/ 62.5% HCV 100% 0% A, 71.9% EV 62.5% 31.3% 545 48.9 ± 4. B, 28.1% Sharma (2013) India NA 174 49.3 ± 11.7 88.5% Alcohol 44.3% 0% A, 31.6% EV 71.3% 44.8% 1023.2 (optimal) HBV 13.2% HCV 16.7% Unknown 25.9% Al-Dahshan (2012) Egypt NA 60 52.62 ± 8.22 78.3% HBV 81.7% 0% NA EV 66.7% NA 1023 HCV 18.3% Colecchia (2012) Italy Prospective 100 54 71.0% HCV 100% 0% A, 68% EV 53.0% 49.0% 1883 (optimal) 513 Mahassadi (2012) Cote d’Ivoire NA (training sample) 111 49 70.3% Alcohol 20.7% 0% A, 22.5% EV 76.6% 70.3% 868 NA (validation sample) 91 50 64.2% Alcohol 26.4% 0% A, 19.8% EV 79.1% 65.9% 868 Mangone (2012) Italy Prospective 87 62.8 58.6% Alcohol 8% NA A, 90.8% EV 35.6% NA 936.364 (optimal) HBV 10.5% HCV 63.2% Others 18.3% Nisar (2012) Pakistan Cross-sectional 150 50.99 ± 12.99 54.0% NA NA NA EV 68.0% NA 909 Abu El Makarem (2011) Egypt Prospective 175 48 65.7% HCV 100% NA A, 26.3% EV 74.9% NA 939.7 B, 33.7% C, 40% Agha (2011) Italy Prospective 43 61 70.0% Schistosomiasis 100% NA NA EV 72.1% 44.2% 885 Cherian (2011) India Prospective 229 42 61.6% Alcohol 42.4% 0% A, 18.3% EV 77.7% 35.4% 666 HBV 15.3% HCV 10% Others 12.7% Unknown 19.7% Esmat (2011) Egypt Prospective 100 49.2 ± 8 48.0% HCV 100% NA A, 20% EV 82.0% 60.0% 1326.6 (optimal) B, 31% C, 49% Mosqueira (2011) Peru Retrospective 47 60.74 50.0% Alcohol 25.5% NA NA EV 74.5% 46.8% 909 HBV 2.1% HCV 14.9% Autoimmune 8.5% Unknown 48.9% Stefanescu (2011) Romania Prospective 137 56 56.2% Alcohol/HCV 100% NA A, 64.9% EV 84.9% 44.0% 1068 B, 28.4% C, 6.8% Barikbin (2010) Iran Prospective 50 52.1 ± 16.2 82.0% Alcohol 4% 0% A, 10% EV 74.0% 62.0% 921 HBV 38% HCV 14% Others 6% Unknown 38% De Mattos (2010) Brazil NA 164 56.6 ± 11.6 56.7% Alcohol 29.3% NA A, 57.6% EV 73.2% 40.8% 909 Viral hepatitis 43.9% Viral hepatitis and alcohol 10.4% Others 16.5% Nashaat (2010) Egypt NA 50 49.6 ± 8.8 74.0% HBV 20% NA A, 38% EV 88.0% NA 820 HCV 70% B, 42% HBV and HCV 10% C, 20% Sarangapani (2010) India Prospective 106 45 67.9% Alcohol 58.5% 0% NA EV 72.6% 48.1% NA% HBV 21.7% Others 19.8% Schwarzenberger (2010) US Retrospective 137 56 64.0% Alcohol 18% NA NA EV 55.5% 18.2% 909 HBV 23% HCV 34% Others 17% Unknown 9 Agha (2009) Pakistan Prospective 311 49 55.6% HCV 100% 0% A, 25.8% EV 49.5% 12.9% 909 B, 58.6% C, 15.6% Barrera (2009) Chile Prospective 67 66 ± 12.2 43.3% Alcohol 26.9% NA A, 46.2% EV 85.1% 49.3% NA Viral hepatitis 7.5% PBC 14.9% Others 26.8% Unknown 26.9% Cammà (2009) Italy Prospective 104 61.4 ± 9.5 57.7% HCV 100% 0% A, 100% EV 60.6% NA 792 Sharif (2009) Pakistan Cross-sectional 100 NA 56.0% HBV 29% NA NA EV 50.0% NA 2200 HCV 71% Baig (2008) India Prospective 150 51 84.0% Alcohol 48.7% NA A, 64.7% EV 70.7% 46.7% 1014 (optimal) Parrino (2008) Italy NA 158 66.6 ± 9.6 63.3% NA 0% A, 64% EV 74.1% 19.6% 1300 B, 31% C, 5% Tao (2008) China NA 69 53 63.8% HBV 100% NA A, 20.3% EV 78.3% NA 909 B, 63.8% C, 15.9% Yu (2008) China Retrospective 89 53 82.0% HBV 100% NA A, 29.2% EV 75.3% 29.2% 909 B, 42.7% C, 28.1% Lei (2007) China Retrospective 326 55 77.3% Alcohol 4.3% NA A, 14.7% EV 41.7% 15.6% 0.55 (optimal) Giannini (2006) Italy Prospective 218 58.7% Alcohol 18.8% 8.7% A, 50.9% EV 54.1% 21.6% 909 Viral hepatitis 48.2% PBC 16.1% Viral hepatitis and alcohol 12.4% Others 4.6% Legasto (2006) Philippines Cross-sectional 150 70.7% Alcohol 90% 0% NA EV 46.0% NA 160 (optimal) Sethar (2006) Pakistan Cross-sectional 113 37.1 ± 14.85 69.0% HBV 33.6% NA A, 13.3% EV 58.4% NA 1445 HCV 52.2% HBV + HCV 7.1% Others 7.1% Giannini (2005) Italy Prospective 68 65 ± 10 63.2% Viral, 77.9% NA A, 35.3% EV 40.0% 5.9% 909 Nonviral, 22.1% B, 41.2% C, 23.5% Pleština (2005) Croatia NA 99 53.6 ± 9.76 78.8% HCV/HBV 13.1% 0% A, 20.2% EV 100.0% 53.5% NA B, 53.5% C, 25.3% Unknown, 1% Giannini (2003) Italy Retrospective 145 61 71.0% Alcohol 16.6% NA A, 37% EV 61.0% 20.0% 909 121 64 65.3% Alcohol 24% NA A, 41.3% EV 58.7% 15.7% 909 HBV 5% HCV 63.6% Others 7.4%
